Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer

E. S. Antonarakis, A. J. Armstrong

Research output: Contribution to journalReview articlepeer-review

Abstract

The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forward in the past year, with the demonstration of improved overall survival with three novel agents (sipuleucel-T, cabazitaxel with prednisone and abiraterone acetate with prednisone), and a significant delay in skeletal-related events observed with denosumab. The pipeline of systemic therapies in prostate cancer remains strong, as multiple agents with a diverse array of mechanisms of action are showing preliminary signs of clinical benefit, leading to more definitive phase III confirmatory trials. In this review, which represents part 1 of a two-part series on metastatic CRPC, we will summarize the mechanisms of resistance to hormonal and chemotherapies and discuss the evolving landscape of treatment options for men with CRPC, with a particular focus on currently approved and emerging treatment options following docetaxel administration, as well as prognostic factors in this post-docetaxel state. As docetaxel remains the standard initial systemic therapy for men with metastatic CRPC for both palliative and life-prolonging purposes, knowledge of these evolving standards will help to optimize delivery of care and long-term outcomes.

Original languageEnglish (US)
Pages (from-to)192-205
Number of pages14
JournalProstate Cancer and Prostatic Diseases
Volume14
Issue number3
DOIs
StatePublished - Sep 2011

Keywords

  • abiraterone
  • cabazitaxel
  • castrate-resistant prostate cancer
  • docetaxel-refractory
  • sipuleucel-T

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this